BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 24512523)

  • 21. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
    Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
    Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening, identification of prostate cancer urinary biomarkers and verification of important spots.
    Zhao H; Zhao X; Lei T; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):935-947. PubMed ID: 30610587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Diagnostic and Prognostic MicroRNA Biomarkers for Prostate Cancer in Cell-free Urine.
    Fredsøe J; Rasmussen AKI; Thomsen AR; Mouritzen P; Høyer S; Borre M; Ørntoft TF; Sørensen KD
    Eur Urol Focus; 2018 Dec; 4(6):825-833. PubMed ID: 28753866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate-specific antigen and other serum and urine markers in prostate cancer.
    Stephan C; Ralla B; Jung K
    Biochim Biophys Acta; 2014 Aug; 1846(1):99-112. PubMed ID: 24727384
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel algorithm for the prediction of prostate cancer in clinically suspected patients.
    Gallotta A; Ziglioli F; Ferretti S; Maestroni U; Moretti M; Aloe R; Gnocchi C; Di Palo M; Fassina G
    Cancer Biomark; 2013; 13(4):227-34. PubMed ID: 24240583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.
    Becker C; Piironen T; Pettersson K; Björk T; Wojno KJ; Oesterling JE; Lilja H
    J Urol; 2000 Jan; 163(1):311-6. PubMed ID: 10604382
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic accuracy of Prostate Health Index and urinary Prostate Cancer Antigen 3 in predicting pathologic features after radical prostatectomy.
    Cantiello F; Russo GI; Ferro M; Cicione A; Cimino S; Favilla V; Perdonà S; Bottero D; Terracciano D; De Cobelli O; Morgia G; Damiano R
    Urol Oncol; 2015 Apr; 33(4):163.e15-23. PubMed ID: 25575715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel potential serological prostate cancer biomarkers using CT100+ cancer antigen microarray platform in a multi-cultural South African cohort.
    Adeola HA; Smith M; Kaestner L; Blackburn JM; Zerbini LF
    Oncotarget; 2016 Mar; 7(12):13945-64. PubMed ID: 26885621
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Detection of urine DD3/PSA mRNA ratio by duplex TaqMan RT-PCR assay and evolution of its primary application].
    Chen FP; Chen LL; Shen M; Chen W; Tao ZH; Wu XL; Hu YP; Li CD; Chen ZG; Chen XD
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(4):261-4. PubMed ID: 18361839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [PCA3 AND TMPRSS2:ERG GENES EXPRESSION IN BIOPSIES OF BENIGN PROSTATE HYPERPLASIA, INTRAEPITHELIAL NEOPLASIA, AND PROSTATE CANCER].
    Mikhaylenko DS; Perepechin DV; Grigoryeva MV; Zhinzhilo TA; Safronova NY; Efremov GD; Sivkov AV
    Urologiia; 2015; (5):46-50. PubMed ID: 26859937
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine.
    Cao DL; Ye DW; Zhu Y; Zhang HL; Wang YX; Yao XD
    Prostate Cancer Prostatic Dis; 2011 Jun; 14(2):166-72. PubMed ID: 21321584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of prostate cancer gene 3 score, prostate health index and percentage free prostate-specific antigen for differentiating histological inflammation from prostate cancer and other non-neoplastic alterations of the prostate at initial biopsy.
    De Luca S; Passera R; Bollito E; Manfredi M; Scarpa RM; Sottile A; Randone DF; Porpiglia F
    Anticancer Res; 2014 Dec; 34(12):7159-65. PubMed ID: 25503144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined serum and EPS-urine proteomic analysis using iTRAQ technology for discovery of potential prostate cancer biomarkers.
    Zhang M; Chen L; Yuan Z; Yang Z; Li Y; Shan L; Yin B; Fei X; Miao J; Song Y
    Discov Med; 2016 Nov; 22(122):281-295. PubMed ID: 28009970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the plasma level of long non-coding RNA PCAT1 in prostatic hyperplasia and newly diagnosed prostate cancer patients.
    Rezatabar S; Moudi E; Sadeghi F; Khafri S; Kopi TA; Parsian H
    J Gene Med; 2020 Oct; 22(10):e3239. PubMed ID: 32529802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of two gene panels for prostate cancer diagnosis and patient risk stratification.
    Xiao K; Guo J; Zhang X; Feng X; Zhang H; Cheng Z; Johnson H; Persson JL; Chen L
    Tumour Biol; 2016 Aug; 37(8):10115-22. PubMed ID: 26820133
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?
    Heidegger I; Höfer J; Luger M; Pichler R; Klocker H; Horninger W; Steiner E; Jochberger S; Culig Z
    Prostate; 2015 Dec; 75(16):1904-9. PubMed ID: 26306920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers.
    Talesa VN; Antognelli C; Del Buono C; Stracci F; Serva MR; Cottini E; Mearini E
    Cancer Biomark; 2009; 5(6):241-51. PubMed ID: 20037200
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.